-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2015-02-26
Target enrollment:
Participant gender:
Summary
Background:
- PF-02341066 and PF-00299804 are drugs that specifically target certain proteins that may be
more active in cancer cells than normal cells, in particular in non-small cell lung cancer.
Both drugs seem to be able to stop the growth of or kill cancer cells. Researchers want to
combine them to see if they are a safe and effective treatment for advanced non-small cell
lung cancer.
Objectives:
- To test the safety and effectiveness of PF-02341066 and PF-00299804 for advanced non-small
cell lung cancer.
Eligibility:
- Individuals at least 18 years of age with advanced non-small cell lung cancer that has not
responded to standard treatments.
Design:
- Participants will be screened with a medical history and physical exam. They will also
have blood and urine tests, and imaging studies. Heart and lung function tests and an
eye exam may also be given.
- The first cycle of treatment will be 28 days. Every cycle after the first will be 21
days. Participants may have up to 17 cycles of treatment.
- Participants will take both study drugs as tablets. Twelve hours after the first dose,
participants will take only the PF-02341066. This dose schedule will remain the same
throughout the study.
- Participants will be monitored with frequent blood and urine tests and imaging studies.
Tumor biopsies will be taken as needed. Those in the study will keep a diary to record
any symptoms or side effects of taking the study drugs.
- After 17 cycles of treatment, or after stopping the study drugs early for any other
reason, participants will have a final followup visit.